Navigation Links
Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China

BRUSSELS, May 18 /PRNewswire/ -- Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global codevelopment of novel biopharmaceutical product opportunities originating in China.

Through this agreement, Solvay Pharmaceuticals will gain access to HUYA's comprehensive Chinese molecule portfolio, focusing specifically on compounds in the cardiovascular area. As some of these molecules are already in advanced stages of development in China, the partnership will help Solvay Pharmaceuticals speed up its early discovery activities as well as increase the company's chances for successfully developing innovative new therapies as safety or efficacy information is already available for some of these molecules.

The pace and quality of China's innovation in the life sciences have led to a significant increase in new product opportunities. Through key collaborations with China's leading academic and commercial organizations, HUYA has gained access to these opportunities to enable and accelerate their worldwide development and commercialization. HUYA has thereby built a most comprehensive Chinese compound portfolio, including a significant number of product candidates targeting cardiovascular diseases to which Solvay Pharmaceuticals will have access under this strategic partnership.

"We look forward to working with HUYA and its highly qualified Chinese partners to identify innovative new molecules and develop them into break-through new therapies for patients and physicians around the globe," said Werner Cautreels, PhD, CEO of Solvay Pharmaceuticals. "We believe that through this partnership, we will be able to speed up our R&D activities by gaining access to compounds that could be introduced in more advanced stages of early development."

According to Mireille Gingras, PhD, President and CEO of HUYA, "This partnership with Solvay Pharmaceuticals further validates HUYA's model for co-developing in Western markets novel therapeutic compounds sourced from China. Moreover, it leverages our demonstrated capabilities and experience in cardiovascular drug development. We are pleased to partner with Solvay Pharmaceuticals on new opportunities for development."

About Solvay Pharmaceuticals

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. The companies seek to fulfil carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2008 sales were EUR 2.7 billion and it employs more than 9,000 people worldwide. For more information, visit

About HUYA Bioscience International

HUYA Bioscience International is a leader in enabling and accelerating the global codevelopment of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical academic and commercial organizations to speed development and value creation in world-wide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA is jointly headquartered in San Diego, CA, and Shanghai, PRC. Additional information about the company is available at

    For more information, please contact:

    Media contacts HUYA Bioscience International:
    Juliet Travis
    (510) 452-3771

    Solvay Pharmaceuticals:
    Sven Voet
    Global Communications
    Phone: + 32 2 509 68 11

    HUYA Bioscience International:
    USA:                               China:
    Jan Tuttleman, PhD                 Li Zhu, PhD
    Vice President, Marketing          VP China Operations
    HUYA Bioscience International,     LLC HUYA Bioscience International, LLC
    (858) 798-8800                     86 (21) 51323312   

SOURCE Solvay Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
2. 40 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM)
3. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
(Date:11/25/2015)... Muncie, IN (PRWEB) , ... November 25, 2015 ... ... Aeronautics (AMA) and the Organization of Black Aerospace Professionals (OPBAP) has been formalized ... Mathewson and other AMA team leaders met with OPBAP leaders Capt. Karl Minter ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
Breaking Biology Technology:
(Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
(Date:10/26/2015)... LAS VEGAS , Oct. 26, 2015 ... an innovator in modern authentication and a founding member ... launch of its latest version of the Nok Nok™ ... to use standards-based authentication that supports existing and emerging ... Suite is ideal for organizations deploying customer-facing applications that ...
Breaking Biology News(10 mins):